PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches

• Gelsoft Plus Vascular Graft (Device), also known as Gelsoft Plus: Gelatin coated, knitted vascular prosthesis implanted to act as a conduit for channeling blood during repair of damaged or diseased vessels.
• Vascular Bypass Graft (Device), also known as Gelsoft Plus Extra Anatomical: Gelatin coated, knitted vascular prosthesis implanted to act as an extra-anatomical bypass for channeling blood during repair of damaged or diseased vessels.
• Cardiovascular Patch (Device), also known as Gelseal Patch, Gelsoft Patch, Thinwall Patch, Cardiovascular Fabrics: Cardiovascular knitted polyester patches are frequently used to treat the carotid or femoral arteries to prevent stroke and repair damage to vessels.
• Gelweave Vascular Graft (Device), also known as Gelweave: The Gelweave woven polyester vascular graft allows replacement of large sections of arteries and, following anastomosis to the native blood vessel, provides a stable conduit for blood flow.
• Gelweave Valsalva Vascular Graft (Device), also known as Gelweave Valsalva: This woven polyester graft is designed to match the aortic root anatomy and is implanted to repair or replace a portion of the aorta in case of an aneurysm, dissection or coarctation at the level of the thoracic aorta.

Primary outcomes

• Operative Death [1 Year]: 30 Day or In-Hospital Mortality
• Graft Leakage [1 Year]: Device Failure: The presence of leakage or excessive bleeding through graft/patch

Secondary outcomes

• Device Endpoints [1 Year]: Device failures, requirement for reintervention or device related adverse events
• Procedural Endpoints [1 Year]: Rifampicin or heparin soaking, procedure related adverse events
• Safety Endpoints [1 Year]: Occurrence of the following: Mortality, Ischemia, Occlusion, Thrombosis, Haemmorrhage, Rupture, Pseudoaneurysm, Stroke

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Patients must meet all of the following inclusion criteria in order to be eligible for inclusion in the study:

All Patients:

* Patient meets the minimum age as per local regulations at time of consent
* Patient requires treatment with study device(s) according to the IFU(s)
* Patient is willing and able to comply with all SOC procedures and study visits
* Patient or their legally authorised representative (LAR) has given written informed consent to participate in study, including consent to collect data retrospectively

  * For prospective emergency patients, retrospective consent is permissible
  * For retrospective patients who are deceased at time of enrollment, local EC regulations relating to consent process should be followed.

Retrospective Patients only:

* Patient has a minimum of 1 year post-operative follow-up data available, or complete data to death.
* Patient implant date is no more than 5 years prior to study start date.

Exclusion Criteria:

* Any patient who meets any of the following exclusion criteria will be excluded from participation in the study:

  * Patient is unable or unwilling to comply with the SOC procedures or follow-up regime
  * Patient is contraindicated per the device IFU
  * Patient has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre- and post-procedure